PD Dr. Christian Rothermundt
Medizinische Onkologie und Hämatologie · Dept. I
BRCA2 germline mutation carrier with five malignancies: a case report.
Su E, Christinat Y, McKee T, Azzarello-Burri S, Jochum W, Fischer S, Rothermundt C. BRCA2 germline mutation carrier with five malignancies: a case report. Hered Cancer Clin Pract 2024; 22:27.
Dec 19, 2024BRCA2 germline mutation carrier with five malignancies: a case report.
Dec 19, 2024Hered Cancer Clin Pract 2024; 22:27
Su Elena, Christinat Yann, McKee Thomas, Azzarello-Burri Silvia, Jochum Wolfram, Fischer Stefanie, Rothermundt Christian
Factors Guiding Clinical Decision-Making in Genitourinary Oncology.
Wosny M, Aeppli S, Fischer S, Peres T, Rothermundt C, Hastings J. Factors Guiding Clinical Decision-Making in Genitourinary Oncology. Cancer Med 2024; 13:e70304.
Oct 1, 2024Factors Guiding Clinical Decision-Making in Genitourinary Oncology.
Oct 1, 2024Cancer Med 2024; 13:e70304
Wosny Marie, Aeppli Stefanie, Fischer Stefanie, Peres Tobias, Rothermundt Christian, Hastings Janna
First Indicator of Relapse in Testicular Cancer and Implications for Follow-up: Analysis of the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS).
Fischer S, Gillessen S, Stalder O, Terbuch A, Cathomas R, Schmid F, Zihler D, Müller-Stich B, Fankhauser C, Hirschi-Blickenstorfer A, Alex Kluth L, Seifert B, Templeton A, Mingrone W, Ufe M, Fischer N, Beyer J, Woelky R, Omlin A, Vogl U, Hoppe K, Kamradt J, Rothschild S, Rothermundt C. First Indicator of Relapse in Testicular Cancer and Implications for Follow-up: Analysis of the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS). Eur Urol Open Sci 2024; 68:68-74.
Sep 11, 2024First Indicator of Relapse in Testicular Cancer and Implications for Follow-up: Analysis of the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS).
Sep 11, 2024Eur Urol Open Sci 2024; 68:68-74
Fischer Stefanie, Gillessen Silke, Stalder Odile, Terbuch Angelika, Cathomas Richard, Schmid Florian, Zihler Deborah, Müller-Stich Beat P, Fankhauser Christian Daniel, Hirschi-Blickenstorfer Anita, Alex Kluth Luis, Seifert Bettina, Templeton Arnoud J, Mingrone Walter, Ufe Mark-Peter, Fischer Natalie Fischer, Beyer Jörg, Woelky Regina, Omlin Aurelius, Vogl Ursula M, Hoppe Katharina, Kamradt Jörn, Rothschild Sacha I, Rothermundt Christian
Electrodiagnostic Biomarkers in Paraneoplastic Retinopathy.
Gougoulakis L, Rothermundt C, Flynn M, Jörger M, Todorova M. Electrodiagnostic Biomarkers in Paraneoplastic Retinopathy. Klin Monbl Augenheilkd 2024; 241:510-524.
Apr 23, 2024Electrodiagnostic Biomarkers in Paraneoplastic Retinopathy.
Apr 23, 2024Klin Monbl Augenheilkd 2024; 241:510-524
Gougoulakis Laura Sophie, Rothermundt Christian, Flynn Marie-Claire, Jörger Markus, Todorova Margarita
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer.
Peres T, Aeppli S, Fischer S, Gysel K, Rothermundt C. Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer. J Cancer Res Clin Oncol 2024; 150:84.
Feb 8, 2024Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer.
Feb 8, 2024J Cancer Res Clin Oncol 2024; 150:84
Peres Tobias, Aeppli Stefanie, Fischer Stefanie, Gysel Katrin, Rothermundt Christian
SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial.
Digklia A, Kollár A, Felber Dietrich D, Kronig M, Britschgi C, Rordorf T, Jörger M, Krasniqi F, Metaxas Y, Colombo I, Ribi K, Rothermundt C. SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial. Eur J Cancer 2023; 197:113470.
Dec 9, 2023SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial.
Dec 9, 2023Eur J Cancer 2023; 197:113470
Digklia Antonia, Kollár Attila, Felber Dietrich Denise, Kronig M N, Britschgi Christian, Rordorf Tamara, Jörger Markus, Krasniqi Fatime, Metaxas Yannis, Colombo Ilaria, Ribi Karin, Rothermundt Christian
Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines Office.
Boormans J, Sylvester R, Anson-Cartwright L, Glicksman R, Hamilton R, Hahn E, Daugaard G, Lauritsen J, Wagner T, Avuzzi B, Nicolai N, del Muro X, Aparicio J, Stalder O, Rothermundt C, Fischer S, Laguna M. Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines Office. Eur Urol Oncol 2023
Nov 9, 2023Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines Office.
Nov 9, 2023Eur Urol Oncol 2023
Boormans Joost L, Sylvester Richard, Anson-Cartwright Lynn, Glicksman Rachel M, Hamilton Robert J, Hahn Ezra, Daugaard Gedske, Lauritsen Jakob, Wagner Thomas, Avuzzi Barbara, Nicolai Nicola, del Muro Xavier Garcia, Aparicio Jorge, Stalder Odile, Rothermundt Christian, Fischer Stefanie, Laguna Maria P
Personalized Therapy of Sarcomas.
Desar I, Rothermundt C. Personalized Therapy of Sarcomas. Cancers (Basel) 2023; 15
Oct 23, 2023Personalized Therapy of Sarcomas.
Oct 23, 2023Cancers (Basel) 2023; 15
Desar Ingrid M E, Rothermundt Christian
Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice Experiment.
Menges D, Piatti M, Omlin A, Cathomas R, Benamran D, Fischer S, Iselin C, Kueng M, Lorch A, Prause L, Rothermundt C, O'Meara Stern A, Zihler D, Lippuner M, Braun J, Cerny T, Puhan M. Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice Experiment. Eur Urol Open Sci 2023; 51:26-38.
Mar 22, 2023Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice Experiment.
Mar 22, 2023Eur Urol Open Sci 2023; 51:26-38
Menges Dominik, Piatti Michela C, Omlin Aurelius, Cathomas Richard, Benamran Daniel, Fischer Stefanie, Iselin Christophe E, Kueng Marc, Lorch Anja, Prause Lukas, Rothermundt Christian, O'Meara Stern Alix, Zihler Deborah, Lippuner Max, Braun Julia, Cerny Thomas, Puhan Milo Alan
The Value of Tumour Markers in the Detection of Relapse-Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study.
Fischer S, Rothermundt C, Stalder O, Terbuch A, Hermanns T, Zihler D, Müller-Stich B, Fankhauser C, Hirschi-Blickenstorfer A, Seifert B, Alex Kluth L, Ufe M, Mingrone W, Templeton A, Fischer N, Rothschild S, Woelky R, Gillessen S, Cathomas R. The Value of Tumour Markers in the Detection of Relapse-Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study. Eur Urol Open Sci 2023; 50:57-60.
Feb 20, 2023The Value of Tumour Markers in the Detection of Relapse-Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study.
Feb 20, 2023Eur Urol Open Sci 2023; 50:57-60
Fischer Stefanie, Rothermundt Christian, Stalder Odile, Terbuch Angelika, Hermanns Thomas, Zihler Deborah, Müller-Stich Beat P, Fankhauser Christian Daniel, Hirschi-Blickenstorfer Anita, Seifert Bettina, Alex Kluth Luis, Ufe Mark-Peter, Mingrone Walter, Templeton Arnoud J, Fischer Natalie Fischer, Rothschild Sacha I, Woelky Regina, Gillessen Silke, Cathomas Richard
Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland.
Çakar E, Oniangue-Ndza C, Schneider R, Klijn S, Vogl U, Rothermundt C, May J. Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland. Pharmacoecon Open 2023
Feb 9, 2023Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland.
Feb 9, 2023Pharmacoecon Open 2023
Çakar Esra, Oniangue-Ndza César, Schneider Ralph P, Klijn Sven L, Vogl Ursula M, Rothermundt Christian, May Jessica R
A global collaboRAtive study of CIC-rearranged, BCOR::CCNB3-rearranged and other ultra-rare unclassified undifferentiated small round cell sarcomas (GRACefUl).
Palmerini E, Gambarotti M, Italiano A, Nathenson M, Ratan R, Dileo P, Provenzano S, Jones R, DuBois S, Martin-Broto J, de Alava E, Baldi G, Grignani G, Ferraresi V, Brunello A, Paoluzzi L, Bertulli R, Hindi N, Montemurro M, Rothermundt C, Cocchi S, Salguero-Aranda C, Donati D, Martin J, Abdelhamid Ahmed A, Mazzocca A, Carretta E, Cesari M, Pierini M, Righi A, Sbaraglia M, Laginestra M, Scotlandi K, Dei Tos A, Ibrahim T, Stacchiotti S, Vincenzi B. A global collaboRAtive study of CIC-rearranged, BCOR::CCNB3-rearranged and other ultra-rare unclassified undifferentiated small round cell sarcomas (GRACefUl). Eur J Cancer 2023; 183:11-23.
Jan 18, 2023A global collaboRAtive study of CIC-rearranged, BCOR::CCNB3-rearranged and other ultra-rare unclassified undifferentiated small round cell sarcomas (GRACefUl).
Jan 18, 2023Eur J Cancer 2023; 183:11-23
Palmerini Emanuela, Gambarotti Marco, Italiano Antoine, Nathenson Michael J, Ratan Ravin, Dileo Palma, Provenzano Salvatore, Jones Robin L, DuBois Steven G, Martin-Broto Javier, de Alava Enrique, Baldi Giacomo G, Grignani Giovanni, Ferraresi Virginia, Brunello Antonella, Paoluzzi Luca, Bertulli Rossella, Hindi Nadia, Montemurro Michael, Rothermundt Christian, Cocchi Stefania, Salguero-Aranda Carmen, Donati Davide, Martin Juan D, Abdelhamid Ahmed Amr H, Mazzocca Alessandro, Carretta Elisa, Cesari Marilena, Pierini Michela, Righi Alberto, Sbaraglia Marta, Laginestra Maria A, Scotlandi Katia, Dei Tos Angelo P, Ibrahim Toni, Stacchiotti Silvia, Vincenzi Bruno
Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence.
Christiansen A, Lobo J, Fankhauser C, Rothermundt C, Cathomas R, Batavia A, Grogg J, Templeton A, Hirschi-Blickenstorfer A, Lorch A, Gillessen S, Moch H, Beyer J, Hermanns T. Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence. Front Oncol 2022; 12:1056823.
Dec 8, 2022Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence.
Dec 8, 2022Front Oncol 2022; 12:1056823
Christiansen Ailsa J, Lobo João, Fankhauser Christian D, Rothermundt Christian, Cathomas Richard, Batavia Aashil A, Grogg Josias B, Templeton Arnoud J, Hirschi-Blickenstorfer Anita, Lorch Anja, Gillessen Silke, Moch Holger, Beyer Jörg, Hermanns Thomas
Von-Hippel-Lindau-Erkrankung
Koster K, Rothermundt C, Binet F, Borovicka J, Bozinov O, Clerici T, Engeler D, Greiner J, Hader C, Heinimann K, Azzarello-Burri S, Lang C, Krull I, Stöckli S, Omlin A, Hundsberger T. Von-Hippel-Lindau-Erkrankung - Interdisziplinäre Betreuung und neue therapeutische Optionen. Swiss Med Forum 2022; 48:4-784-787.
Nov 30, 2022Von-Hippel-Lindau-Erkrankung
Nov 30, 2022Swiss Med Forum 2022; 48:4-784-787
Koster Kira-Lee, Rothermundt Christian, Binet Françoise-Isabelle, Borovicka Jan, Bozinov Oliver, Clerici Thomas, Engeler Daniel, Greiner J, Hader Claudia, Heinimann Karl, Azzarello-Burri Silvia, Lang Corina, Krull Ina, Stöckli Sandro, Omlin Aurelius, Hundsberger Thomas
Controversies in the management of patients with soft tissue sarcoma: Recommendations of the Conference on State of Science in Sarcoma 2022.
Rothermundt C, Andreou D, Blay J, Brodowicz T, Desar I, Dileo P, Gelderblom H, Haas R, Jakob J, Jones R, Judson I, Kunz W, Liegl-Atzwanger B, Lindner L, Messiou C, Miah A, Reichardt P, Szkandera J, van der Graaf W, van Houdt W, Wardelmann E, Hofer S. Controversies in the management of patients with soft tissue sarcoma: Recommendations of the Conference on State of Science in Sarcoma 2022. Eur J Cancer 2022; 180:158-179.
Nov 16, 2022Controversies in the management of patients with soft tissue sarcoma: Recommendations of the Conference on State of Science in Sarcoma 2022.
Nov 16, 2022Eur J Cancer 2022; 180:158-179
Rothermundt Christian, Andreou Dimosthenis, Blay Jean-Yves, Brodowicz Thomas, Desar Ingrid M E, Dileo Palma, Gelderblom Hans, Haas Rick, Jakob Jens, Jones Robin L, Judson Ian, Kunz Wolfgang G, Liegl-Atzwanger Berndadette, Lindner Lars H, Messiou Christina, Miah Aisha, Reichardt Peter, Szkandera Joanna, van der Graaf Winette T A, van Houdt Winan J, Wardelmann Eva, Hofer Silvia
Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic Review.
Neuenschwander A, Lonati C, Antonelli L, Papachristofilou A, Cathomas R, Rothermundt C, Templeton A, Gulamhusein A, Fischer S, Gillessen S, Hermanns T, Lorch A, Mattei A, Fankhauser C. Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic Review. Eur Urol Focus 2022
Nov 12, 2022Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic Review.
Nov 12, 2022Eur Urol Focus 2022
Neuenschwander Anne, Lonati Chiara, Antonelli Luca, Papachristofilou Alexandros, Cathomas Richard, Rothermundt Christian, Templeton Arnoud J, Gulamhusein Aziz, Fischer Stefanie, Gillessen Silke, Hermanns Thomas, Lorch Anja, Mattei Agostino, Fankhauser Christian D
Reply to Julian Chavarriaga and Robert Hamilton's Letter to the Editor re: Manolis Pratsinis, Christian Fankhauser, Katerina Pratsinis, et al. Metastatic Potential of Small Testicular Germ Cell Tumors: Implications for Surveillance of Small Testicular Masses. Eur Urol Open Sci 2022;40:16-8. Should We Be Afraid of Surveillance? Clinically Meaningful Reasons Why Offering Surveillance for Incidentally Detected Small Testicular Masses Remains a Safe Approach.
Pratsinis M, Rothermundt C, Fankhauser C. Reply to Julian Chavarriaga and Robert Hamilton's Letter to the Editor re: Manolis Pratsinis, Christian Fankhauser, Katerina Pratsinis, et al. Metastatic Potential of Small Testicular Germ Cell Tumors: Implications for Surveillance of Small Testicular Masses. Eur Urol Open Sci 2022;40:16-8. Should We Be Afraid of Surveillance? Clinically Meaningful Reasons Why Offering Surveillance for Incidentally Detected Small Testicular Masses Remains a Safe Approach. Eur Urol Open Sci 2022; 45:52.
Oct 3, 2022Reply to Julian Chavarriaga and Robert Hamilton's Letter to the Editor re: Manolis Pratsinis, Christian Fankhauser, Katerina Pratsinis, et al. Metastatic Potential of Small Testicular Germ Cell Tumors: Implications for Surveillance of Small Testicular Masses. Eur Urol Open Sci 2022;40:16-8. Should We Be Afraid of Surveillance? Clinically Meaningful Reasons Why Offering Surveillance for Incidentally Detected Small Testicular Masses Remains a Safe Approach.
Oct 3, 2022Eur Urol Open Sci 2022; 45:52
Pratsinis Manolis, Rothermundt Christian, Fankhauser Christian
Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment.
Su E, Fischer K, R Demmer-Steingruber, Nigg S, Güsewell S, Albrich W, Rothermundt C, Silzle T, Kahlert C. Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment. ESMO Open 2022; 7:100587.
Aug 24, 2022Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment.
Aug 24, 2022ESMO Open 2022; 7:100587
Su E, Fischer Katharina S, R Demmer-Steingruber, Nigg Susanne, Güsewell Sabine, Albrich Werner, Rothermundt Christian, Silzle Tobias, Kahlert Christian
Alternative splicing of Apoptosis Stimulating Protein of TP53-2 (ASPP2) results in an oncogenic isoform promoting migration and therapy resistance in soft tissue sarcoma (STS).
Tsintari V, Walter B, Fend F, Overkamp M, Rothermundt C, Lopez C, Schittenhelm M, Kampa-Schittenhelm K. Alternative splicing of Apoptosis Stimulating Protein of TP53-2 (ASPP2) results in an oncogenic isoform promoting migration and therapy resistance in soft tissue sarcoma (STS). BMC cancer 2022; 22:725.
Jul 2, 2022Alternative splicing of Apoptosis Stimulating Protein of TP53-2 (ASPP2) results in an oncogenic isoform promoting migration and therapy resistance in soft tissue sarcoma (STS).
Jul 2, 2022BMC cancer 2022; 22:725
Tsintari Vasileia, Walter Bianca, Fend Falko, Overkamp Mathis, Rothermundt Christian, Lopez Charles D, Schittenhelm Marcus, Kampa-Schittenhelm Kerstin
Incidence and outcome of patients with renal cell carcinoma treated with partial or radical nephrectomy in the Cantons St Gallen and Appenzell 2009-2018.
Aeppli S, Engeler D, Fischer S, Omlin A, Pratsinis M, Hermann C, Rothermundt C. Incidence and outcome of patients with renal cell carcinoma treated with partial or radical nephrectomy in the Cantons St Gallen and Appenzell 2009-2018. Swiss Med Wkly 2022; 152:w30175.
Jun 16, 2022Incidence and outcome of patients with renal cell carcinoma treated with partial or radical nephrectomy in the Cantons St Gallen and Appenzell 2009-2018.
Jun 16, 2022Swiss Med Wkly 2022; 152:w30175
Aeppli Stefanie, Engeler Daniel, Fischer Stefanie, Omlin Aurelius, Pratsinis Manolis, Hermann Christian, Rothermundt Christian